IL-22在原发性胆汁性肝硬化中的表达及其临床意义  

Expression of IL-22 in Primary Biliary Cirrhosis and Its Clinical Significance

作　　者：王淇泓[1] 周晔[1] 王爱华[1] 竺蓓[1] 邓安梅[1] 仲人前[1] 

机构地区：[1]第二军医大学长征医院实验诊断科全军临床免疫中心,上海200003

出　　处：《现代检验医学杂志》2010年第1期25-27,共3页Journal of Modern Laboratory Medicine

基　　金：本课题受国家自然科学基金（30671840,30772017,30770997）,上海市科委基金（08QH14001）资助.

摘　　要：目的探讨原发性胆汁性肝硬化（PBC）外周血中IL-22的表达水平及其临床意义。方法采用酶联免疫吸附试验（ELISA）检测PBC患者血清中IL-22水平；全自动生化仪检测TBIL，γ-GT；并以健康体检者为对照组。结果40例PBC患者血清中IL-22水平（810．36±30．52pg／m1）明显高于健康对照组（361．51±30．52pg／ml，P〈0．05），且IL-22水平与TBIL和γ-GT呈显著正相关（r=0．386，P〈0．05；r=0．356，P〈0．05）。结论IL-22可能参与了PBC的发病机制，并可能成为一个潜在的治疗靶点。Objective To investigate the expression of IL-22 in serum of primary biliary cirrhosis （PBC） patients and its clinical significance. Methods The serum IL-22 of PBC patients and healthy controls were measured by ELISA. Its correlation with TBIL and γ-GT were analyzed. Results The serum concentration of IL-22 was higher in PBC patients（810. 36 ± 30.52 pg/ml） than healthy controls （361.51±30. 52 pg/ml, P〈0. 05）. Serum IL-22 concentration was positively correlated with TBIL and γ-GT,the correlation coefficient were 0. 386 and 0. 356（P〈0. 05）. Conclusion IL-22 may be involved in the pathogenesis of and it is a potential therapy target for such a disease.

关 键 词：原发性胆汁性肝硬化 IL-22 酶联免疫吸附试验 

分 类 号：R575.22[医药卫生—消化系统] R392.11[医药卫生—内科学]